Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;6(10):1073-1075.
doi: 10.1016/j.eng.2020.05.015. Epub 2020 Jun 10.

Mesenchymal Stem Cells Represent a Potential Therapeutic Option for Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome

Xuan Zhao  1 , Yi Zhang  1
Affiliations

Mesenchymal Stem Cells Represent a Potential Therapeutic Option for Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome

Xuan Zhao et al. Engineering (Beijing). 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Potential mechanisms involved in MSC therapy for ARDS. MSCs exert therapeutic effects for the treatment of ARDS through different mechanisms. MSCs can secrete a number of factors including IL-10, IL-1 receptor antagonist (Ra), fibroblast growth factor 7 (FGF7), insulin-like growth factor 1 (IGF-1), VEGF, and TGF-β1, reduce the production of pro-inflammatory cytokines including IL-6, tumor necrosis factor (TNF)-α, and IFN-γ, and improve the activity of macrophages. Once recruited and/or entrapped in the local microcirculation and/or pulmonary vasculature, activating factors released from local cells (both endothelium and locally recruited inflammatory cells) are able to stimulate MSCs to release various paracrine mediators, enhancing their ability to regenerate and repair damaged lung tissue. M2 macrophage: alternatively activated macrophage.
See this image and copyright information in PMC

References

    1. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. In press. - PMC - PubMed
    1. Pham T., Rubenfeld G.D. Fifty years of research in ARDS. The epidemiology of acute respiratory distress syndrome. A 50th birthday review. Am J Respir Crit Care Med. 2017;195(7):860–870. - PubMed
    1. Matthay M.A., Zemans R.L., Zimmerman G.A., Arabi Y.M., Beitler J.R., Mercat A. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):19. - PMC - PubMed
    1. Lew T.W., Kwek T.K., Tai D., Earnest A., Loo S., Singh K. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374–380. - PubMed
    1. Cockrell A.S., Yount B.L., Scobey T., Jensen K., Douglas M., Beall A. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016;2(2):16226. - PMC - PubMed

LinkOut - more resources